EyePoint Pharmaceuticals is a healthcare company focused on developing and commercializing innovative ophthalmic therapeutics. Its core products include sustained-release drug delivery systems for treating eye diseases, with a primary emphasis on conditions such as retinal diseases and glaucoma. Major business segments involve product development, regulatory approvals, and commercialization efforts. The company generates revenue primarily through product sales and collaborations with other pharmaceutical entities.
The investment profile of EyePoint Pharmaceuticals is more aligned with value investors due to its current low stock price and potential for recovery. However, the high risk associated with its financial performance and market volatility suggests caution. The stock may not provide immediate returns, making it less suitable for growth-focused investors.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-18 | — | Sell | scenario_deterioration |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-02 | China Renaissance Securities (US) Inc. | Update | — → 4 | 4.58 |
| 2026-08-18 | Chardan Capital | Rating Downgraded | — → 5 | 5.31 |
| 2026-08-18 | RBC Capital | Rating Downgraded | — → 5 | 4.87 |
| 2026-08-17 | Jefferies | Target Lowered | 30 → 8 | 4.605 |
| 2026-08-06 | H.C. Wainwright | Target Lowered | 30 → 27 | 12.25 |
| 2026-07-29 | Mizuho Securities | Target Raised | — → 39 | 11.96 |
| 2026-07-15 | Stifel Nicolaus | Update | — → 40 | 13.85 |
| 2026-02-19 | Mizuho Securities | Target Raised | 33 → 36 | 14.36 |
| 2026-02-05 | RBC Capital | Update | — → 39 | 13.22 |
| 2025-10-29 | Mizuho Securities | Target Raised | 28 → 33 | 12.25 |
| 2025-10-20 | Mizuho Securities | Update | — → 28 | 11.63 |
